GlassScriptPhysician profile
Leanne M Mancini
NPI 1033231253
$3,007.18
in general payments reported to CMS, 2019-2025
27 companies · $610 in 2025
The $610 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $125 · 2021: $444 · 2022: $584 · 2023: $475 · 2024: $440 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,524.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $761.05 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $685.48 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $303.45 | 2021-2025 | |
| Glaxosmithkline, LLC. | $211.74 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.92 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $169.88 | 2022-2025 | |
| Lilly USA, LLC | $142.39 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Astellas Pharma US INC | $60.28 | 2019-2024 | Myrbetriq, Veozah |
| Amarin Pharma, INC. | $44.73 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $40.22 | 2022 | |
| Daiichi Sankyo INC. | $37.92 | 2023-2024 | Injectafer |
| Insulet Corporation | $35.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $34.90 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $33.11 | 2021 | |
| Exact Sciences Corporation | $32.82 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $31.69 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $31.33 | 2019-2023 | Spravato |
| Dexcom, INC. | $30.40 | 2023-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $24.58 | 2023 | Prolia, Evenity |
| Abbott Laboratories | $20.08 | 2024 | Freestyle Libre 3 |
| Shield Therapeutics INC | $19.36 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $15.50 | 2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $14.71 | 2022 | |
| Merck Sharp & Dohme LLC | $13.66 | 2021 | |
| Shire North American Group INC | $12.23 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.04 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leanne Mancini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.